EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Autoantibodies and therapeutic antibodies against complement factor H

Saskia Nugteren, Haiyu Wang, Cees van Kooten, Kyra A Gelderman, Leendert A Trouw

Immunology Letters · 2025-08 · 274 · 107002

DOI: 10.1016/j.imlet.2025.107002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunology Letters, 2025-08. Verfasst von Saskia Nugteren und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Autoantibodies, Complement Factor H. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kidney Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The complement system is a crucial part of our immune defense as, upon recognition, it can kill pathogens fast and effectively. However, misguided complement activation could cause damage to host tissues. Therefore, a well-controlled regulation of the complement system is a necessity to prevent collateral damage. Regulation is achieved by several complement inhibitory proteins, acting at different levels of the complement system. One of these complement regulators is factor H, the main regulator of the alternative complement activation pathway. Factor H can regulate the complement system both in fluid-phase and on the host cell surface by, for example, acting as co-factor for factor I, inactivating C3b. The functional properties of factor H are located within different regions of the protein. Functional impairment of factor H, either because of genetic variants, competing proteins such as the factor H-related proteins and proteins from certain pathogens, but also the presence of autoantibodies will impact on complement activation. However, exact consequences are dependent on the region within factor H that is affected. Autoantibodies binding to factor H have been shown to inhibit several regulatory functions of factor H, which is observed in diseases such as membranoproliferative glomerulonephritis and atypical hemolytic uremic syndrome. As more recently the presence of anti-factor H autoantibodies has also been discovered in several other diseases, ranging from autoimmune diseases to cancer, this review provides an overview of the presence of factor H autoantibodies described in these diseases. Factor H autoantibodies are reported to have inhibitory, or enhancing, effects on factor H, depending on the epitopes that are recognized. Formal conclusions about the pathogenicity of the factor H autoantibodies in some of these diseases cannot be drawn yet. Importantly, understanding the binding and functional impact of anti-factor H (auto)antibodies will allow targeted interventions to diminish pathological consequences of anti-factor H autoantibodies but may also open up additional avenues for the use of anti-factor H antibodies as therapeutic agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AutoantibodiesComplement Factor HHumansAnimalsComplement ActivationAutoimmune DiseasesAtypical Hemolytic Uremic SyndromeGlomerulonephritis, MembranoproliferativeNeoplasms

Stichwörter der Autor:innen

AutoantibodiesAutoimmunityComplementFactor HInhibition

Substanzen

AutoantibodiesComplement Factor H

Autor:innen und Institutionen

  • Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands.
  • Department of Internal Medicine section Nephrology, Center of Expertise for Lupus, Vasculitis and Complement- mediated Systemic Autoimmune Diseases, Leiden University Medical Center, Leiden, the Netherlands.
  • Erasmus Medical Center, Department of Immunology, Laboratory Medical Immunology, Rotterdam, the Netherlands.
  • Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands. Electronic address: L.A.Trouw@LUMC.nl.

Förderung

  • Kidney Foundation

Zitieren

APA

Nugteren, S., Wang, H., van Kooten, C., Gelderman, K. A., & Trouw, L. A. (2025). Autoantibodies and therapeutic antibodies against complement factor H. Immunology Letters, 274, 107002. https://doi.org/10.1016/j.imlet.2025.107002

Vancouver

Nugteren S, Wang H, van Kooten C, Gelderman KA, Trouw LA. Autoantibodies and therapeutic antibodies against complement factor H. Immunology Letters. 2025;274:107002. doi:10.1016/j.imlet.2025.107002

BibTeX
@article{Nugteren2025,
  author = {Nugteren, Saskia and Wang, Haiyu and van Kooten, Cees and Gelderman, Kyra A and Trouw, Leendert A},
  title = {Autoantibodies and therapeutic antibodies against complement factor H},
  journal = {Immunology Letters},
  year = {2025},
  volume = {274},
  pages = {107002},
  doi = {10.1016/j.imlet.2025.107002}
}
Kostenlos starten →